Summary
Guardant Health, Inc. reported total revenue of $109.1 million for the second quarter of 2022, a 19% increase year-over-year, driven by a 27% surge in precision oncology testing revenue to $92.1 million. This growth was propelled by higher test volumes from both clinical customers and biopharmaceutical partners. However, the company continued to experience significant operating losses, with a net loss of $229.4 million for the quarter, widening from $97.6 million in the prior year period. This increased loss was primarily due to substantial investments in research and development and sales and marketing, alongside a significant one-time fair value adjustment related to the acquisition of the remaining stake in its joint venture. The company's balance sheet reflects a robust cash position of $1.2 billion in cash and marketable securities as of June 30, 2022, providing a cushion for ongoing operations and investments. Despite the widening net loss, the company has reiterated its belief that current resources are sufficient to fund its operating plan for at least the next twelve months, though it acknowledges the potential need for additional capital if its transition to profitability is not consistent with its plan. Key strategic initiatives include expanding its product pipeline with tests like Shield and Guardant SHIELD, alongside international market penetration, which are expected to drive future growth but also necessitate continued investment.
Financial Highlights
50 data points| Revenue | $109.14M |
| R&D Expenses | $85.45M |
| Operating Expenses | $239.47M |
| Operating Income | -$130.32M |
| Interest Expense | $645K |
| Net Income | -$229.43M |
| EPS (Basic) | $-2.25 |
| EPS (Diluted) | $-2.25 |
| Shares Outstanding (Basic) | 102.05M |
| Shares Outstanding (Diluted) | 102.05M |
Key Highlights
- 1Total revenue increased 19% to $109.1 million in Q2 2022, driven by strong performance in precision oncology testing.
- 2Precision oncology testing revenue grew 27% to $92.1 million, fueled by increased volume from both clinical and biopharmaceutical customers.
- 3Net loss widened significantly to $229.4 million in Q2 2022, compared to $97.6 million in Q2 2021, impacted by increased operating expenses and a one-time fair value adjustment related to the joint venture acquisition.
- 4Cash and marketable securities stood at $1.2 billion as of June 30, 2022, providing substantial liquidity.
- 5Research and development expenses increased by 34% to $85.5 million, reflecting continued investment in product development and clinical studies.
- 6Sales and marketing expenses surged by 54% to $73.6 million, indicating increased efforts in commercial infrastructure buildout and new product launches.
- 7The company completed the acquisition of its joint venture in June 2022, consolidating full control over its international operations in the Asia, Middle East, and Africa regions.